Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 238

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 238
---
 this proxy statement/prospectus solely to provide
FutureTech stockholders access to information made available in connection with the FutureTech Board’s consideration of the Business
Combination. The FutureTech Board reviewed and discussed the Projections in connection with its review of the Business Combination, and
the Projections were provided to Newbridge in connection with its delivery of a fairness opinion with respect to the transactions contemplated
by the Merger Agreement. The Projections should not be viewed as public guidance and are neither fact nor a guarantee of actual future
performance. You are cautioned to consider that the Projections may be materially different than actual results when relying on such Projections
in making a decision regarding the Business Combination, particularly because (i) the Projections span a ten-year time period which creates
a significant risk that such projections will not be achieved and (ii) the Projections assume that all product candidates receive regulatory
approval and there is significant risk that any one or all of Longevity’s product candidates may not receive such approval or receive
approval according the the estimated timelines or, if approved, will not gain market acceptance.

Furthermore, the Projections do not
take into account any circumstances or events occurring after the date on which the Projections were prepared.

Preparation of the Projections

FutureTech and
Longevity do not, as a matter of general practice, publicly disclose long-term forecasts or internal projections of their future performance,
revenue, financial condition or other results. However, in connection with the Business Combination, Longevity’s management prepared
the financial projections set forth herein to present key elements of the financial projections provided to FutureTech. Longevity’s
financial projections were prepared solely for internal use and not with a view toward compliance with the published guidelines of the
SEC or the guidelines established by the American Institute of Certified Public Accountants for the preparation or presentation of prospective
financial information, but, in the view of Longevity’s management team, were prepared on a reasonable basis, reflect the best then-currently
available estimates and judgments and present, to the best of Longevity management’s knowledge and belief, the expected course of
action and the expected future financial performance of each of Aegeria and Cerevast assuming each product candidate obtains regulatory
approval. Further, the Projections were prepared by Longevity’s management in good faith based on its judgment and assumptions regarding
the future financial performance of Longevity and the projected dates of product approval. Please see the “— Material Assumptions for the Forecast by Product